Asked Oct 12, 11:46 AM EDT (midday). Muse Spark 1.1, Perplexity, Gemini 1.5 Pro, DeepSeek, Grok 4.5 and GPT-6 answered the same standard prompt independently. Window: from Oct 12, 11:46 AM EDT to Oct 13, 11:46 AM EDT, the same time one session later. Benchmark: SPY.
Five direction-adjusted close-to-close returns; a down call reverses the sign. The score is the mean signed return, without subtracting the benchmark. In each chart SPY is on the left and the picks on the right, every candle drawn from zero to that asset's move; ✓ marks a pick that moved the way it was called.
| Model | Correct | Hit rate | Return | SPY | Directional return |
|---|---|---|---|---|---|
| Muse Spark 1.1 | 2/5 | 40.00% | -0.75% | -0.30% | -0.75% |
| Perplexity | 3/5 | 60.00% | 2.52% | -0.30% | 2.52% |
| Gemini 1.5 Pro | 3/4 | 75.00% | -0.73% | -0.30% | -0.73% |
| DeepSeek | 2/5 | 40.00% | -0.62% | -0.30% | -0.62% |
| Grok 4.5 | 4/5 | 80.00% | 1.24% | -0.30% | 1.24% |
| GPT-6 | 4/5 | 80.00% | 1.25% | -0.30% | 1.25% |
Muse Spark 1.1
View full picks and reasoning
Oct 9 session was split: 【entity-SpaceX¦canonical_name=SpaceX】 buying Grain Management 800 MHz spectrum for ~$8B crushed carriers and lifted tower REITs, while idiosyncratic upgrades and star ratings drove outsized single-name moves. Expect mean-reversion risk in speculative tower pop and momentum persistence in fundamentally verified upgrades.
- FSLY up — confidence 72%. Top gainer +15.86% to $29.30 at close Oct 9 4pm EDT after Oppenheimer upgrade to Outperform $35 target citing agentic AI traffic monetization and larger contract values. Reported close $29.30 +4.01 (+15.86%)【923471177841542312†L25-L29】. Catalyst substantive analyst-driven but not company issued: published reports said upgrade【2362003852572785745†L27-L32】. Latest quote $26.9 current with open $28.87 high $29 low $26.66 previous close $29.3 change -2.4 (-8.19%)【1530507195814078739†L13-L20】 as of Oct 12, indicating partial retrace but still elevated. Reference price is live/delayed intraday Oct 12, stale vs close. Historical path shows breakout: 10/09 open 26.90 high 30.19 low 26.54 close 29.30 vol 15,175,803【1530507195814078739†L46-L49】 vs prior closes 25.29, 25.28, 25.51, 26.01. Volume spike supports continuation. Counter-evidence: no company release, single analyst, high wick 30.19. Invalidation: close back below $25.29 Oct 8 close would negate upgrade momentum. Market cap ~$4B up 253% YoY【1530507195814078739†L26-L30】 passes $1B. Avg dollar volume 6,360,710 shares avg vol【1530507195814078739†L96-L99】 * $29.3 ~ $186M > $20M.
Return: -0.44%; alpha: -0.14%. - TMUS up — confidence 68%. Top loser -13.27% to $148.58 Oct 9 after 【entity-SpaceX¦canonical_name=SpaceX】 agreed to buy nationwide 800 MHz spectrum for Starlink Mobile. Reported TMUS.US -13.27% 【entity-SpaceX¦canonical_name=SpaceX】 buys 800 MHz spectrum【7840852275757575009†L16-L19】 and close $148.58【7840852275757575009†L22-L25】. Catalyst speculative: threat to carrier moat but no operational network yet; FCC approval pending and $8B price noted【7273514863434464020†L33-L38】. Latest quote $153.00 +4.42 (+2.97%) Oct 12 10:42 AM open【4232354576970514628†L7-L11】 shows bounce, live/delayed regular session, indicating reversal underway. Historical OHLC 10/09 open 155.51 high 156.89 low 147.90 close 148.58 vol 19,028,315【7840852275757575009†L22-L25】 with gap down from 171.31 prior close. 52-week low $147.90 touched, steepest since 2013 debut narrative. Market cap $159.844B as of Oct 9【4232354576970514628†L72-L76】 and $164.12B Oct 12【4232354576970514628†L10-L13】 passes $1B. Dollar volume >$2B. Counter-evidence: broader telecom selloff -9% to -10% peers, not TMUS-specific. Invalidation: close below $147.90 low would signal continuation.
Return: 0.82%; alpha: 1.12%. - HUM up — confidence 70%. Gainer +11.56% to $431.87 Oct 9 on CMS star ratings. Reported as of today HUM price $431.87 up +11.56% on Oct 9 2026【6170058462709517169†L25-L27】 and top movers HUM.US +11.56% largest Medicare Advantage contract restored to 4 stars【6170058462709517169†L64-L67】. Historical OHLC 10/09 open 450.49 high 456.50 low 428.45 close 431.87 vol 4,993,541【6170058462709517169†L14-L19】. Gap up open 450.49 from prior close 387.12. Catalyst substantive: CMS 2027 ratings 95% members in 4+ star plans vs 20% prior, unlocks quality bonus payments. Sources: Humana said 95% of members in 4+ star plans【7827693201590103294†L35-L39】. Latest price $431.87 today as of Oct 9【3238176936453506524†L5-L9】; reference is prior close, regular session. Market cap $51.86B as of Oct 12【3238176936453506524†L5-L9】 and $52B【6170058462709517169†L25-L29】 passes floor. Dollar volume ~$2.1B > $20M. Counter-evidence: closed well off high 456.50 to 431.87, long upper wick suggests profit-taking. Invalidation: close below $387.12 Oct 8 close would erase rating pop.
Return: -1.94%; alpha: -1.63%. - CCI down — confidence 62%. Top gainer +15.60% to $79.64 Oct 9 on inverse telecom trade. Reported CCI price $79.64 up +15.60% Oct 9【4050691196254787578†L11-L15】 and CCI.US +15.60% on SpaceX deal【4050691196254787578†L85-L90】. Catalyst speculative: market reads SpaceX will need tower tenancy; no new contract disclosed, source notes market interpretation not stated cause【7273514863434464020†L5-L10】. Latest quote $79.68 up 0.05% Oct 12 11:14 AM【2108390931644530870†L91-L96】 delayed, prior close was surge. Historical OHLC Oct 09 74.32 open 79.79 high 73.75 low 79.64 close vol 14,389,600【6617501406586374234†L11-L14】 vs Oct 08 69/69.29/67.47/68.89. Gap up 5.43. Market cap $33.666B Oct 09【2108390931644530870†L12-L17】 and $32.945B【2108390931644530870†L25-L28】 passes. Avg daily volume 3,740,193【2108390931644530870†L59-L64】 * price ~ $297M > $20M. Counter-evidence: tower benefit speculative, carrier spend uncertain, stock still down YTD -10.39%. Expect reversal down as gap fades. Invalidation: close above $79.79 high would confirm new uptrend.
Return: -0.25%; alpha: 0.55%. - T down — confidence 65%. Major loser -9.81% to $22.18 Oct 9 same SpaceX overhang. Reported AT&T closed at $22.17 down 9.81%【389542235036383204†L18-L21】 and NYSE T 22.18 -2.41 (-9.81%) at close Oct 9【389542235036383204†L26-L31】. Historical OHLC 10/09 open 22.38 high 23.10 low 21.96 close 22.18 vol 150,534,925【4063896630482465282†L32-L35】. Down gap from 24.87 prior close. Latest quote current price 22.28 open 22.26 high 22.66 low 22.25 previous close 22.18 change +0.10 (+0.45%)【389542235036383204†L9-L14】 Oct 12 delayed. Catalyst speculative competitive threat plus Scotiabank target cut $27.50 to $26.50 noted gap down before open【389542235036383204†L80-L84】. Market cap $151.99B Oct 9【389542235036383204†L32-L36】 and $156.37B current【4063896630482465282†L11-L13】 passes. Dollar volume ~$3.3B > $20M. Direction down continuation as overhang persists into earnings. Counter-evidence: oversold, dividend yield support, bounce to $22.28, some analysts still see limited downside. Invalidation: close above $24.87 Oct 8 close would reverse downtrend.
Return: 2.44%; alpha: -2.14%.
Perplexity
View full picks and reasoning
The source session is Friday, October 9, 2026, the last completed regular session before the prediction time. The market enters Monday cautiously after a record-setting week, with the SpaceX spectrum transaction driving a sharp sector rotation: tower REITs and selected healthcare names rallied, while wireless carriers and satellite-direct-to-device names sold off. I favor selective continuation in fundamentally supported gainers, a reversal in the most extended biotech mover, and a rebound in the most oversold large-cap carrier; I favor continuation lower in AST SpaceMobile because its competitive setback is direct rather than merely sentimental.
- CCI up — confidence 58%. Crown Castle rose 15.60% on October 9 after SpaceX's agreement to buy Grain Management's nationwide 800 MHz spectrum highlighted potential demand for tower leasing; the move closed near the day's high at 79.64 on 14,393,049 shares. The catalyst is partly substantive: additional spectrum deployment can require tower infrastructure, although the immediate reaction is also a sentiment-driven read-through rather than a confirmed new Crown Castle contract. Latest available quote: 79.71 USD in after-hours trading at 2026-10-09T19:59:00-04:00, from https://stockanalysis.com/stocks/cci/ (extended-hours, one trading day stale). I expect continuation higher over the remaining window because the closing position was strong and the thematic catalyst remained fresh, but the 15.6% one-day gain creates pullback risk. Strongest counter-evidence: the stock remains well below its 52-week high of 100.50 and the move is an inference from a competitor's spectrum purchase, not verified incremental revenue. Invalidation: a close back below the October 9 open of 74.32 would undermine the continuation thesis.
Return: -0.25%; alpha: 0.05%. - MRNA down — confidence 55%. Moderna gained 14.21% on October 9 to a new 52-week high of 225.00, aided by its Nasdaq-100 inclusion and continued enthusiasm around its cancer-vaccine program. The inclusion is a mechanical but real demand event; the oncology data are substantive, yet much of the year's re-rating already reflects them. Latest available quote: 225.45 USD in after-hours trading at 2026-10-09T19:59:00-04:00, from https://stockanalysis.com/stocks/mrna/ (extended-hours, one trading day stale). I expect reversal lower: the stock closed at its session high after an extremely extended run, Citi recently downgraded it to Sell on valuation, and the consensus price target of 122.67 is far below the market price. Strongest counter-evidence: index-related demand and positive clinical momentum can sustain gains despite stretched valuation. Invalidation: a future close above 225.45 would negate the reversal thesis.
Return: -1.44%; alpha: 1.74%. - HUM up — confidence 60%. Humana advanced 11.56% on October 9 after reporting that 95% of its Medicare Advantage members will be in plans rated at least four stars for 2027, a materially favorable development for quality bonus revenue. This is a substantive fundamental catalyst, reinforced by Baird's upgrade and multiple price-target increases. Latest available quote: 435.00 USD in after-hours trading at 2026-10-09T19:59:00-04:00, from https://stockanalysis.com/stocks/hum/ (extended-hours, one trading day stale). I expect continuation higher because the ratings improvement directly affects future Medicare Advantage economics and analysts responded with higher estimates; however, the stock opened at 450.49, above its eventual 431.87 close, showing that some enthusiasm faded intraday. Strongest counter-evidence: the October 9 close was below the open and well below the 456.50 high, indicating supply into the rally. Invalidation: a future close below 428.45, the October 9 low, would undermine continuation.
Return: -1.94%; alpha: -1.63%. - TMUS up — confidence 54%. T-Mobile fell 13.27% on October 9 to 148.58, its largest one-day decline in the reviewed period, after SpaceX's spectrum purchase intensified fears of satellite-based wireless competition. The competitive concern is real but its immediate earnings impact is uncertain; the sell-off appears to have discounted a long-dated threat very quickly. Latest available quote: 150.29 USD in pre-market trading at 2026-10-12T05:56:00-04:00, from https://stockanalysis.com/stocks/tmus/ (pre-market, approximately six hours before the answer window's start). I expect reversal higher: the stock closed near its low after touching a 52-week low of 147.90, and Raymond James upgraded it to Outperform with a 170 target shortly before the forecast window. Strongest counter-evidence: the stock has been in a persistent downtrend and the pre-market bounce was only 1.15%, so short covering may not hold. Invalidation: a future close below 147.90, the verified October 9 low and 52-week low, would invalidate the rebound thesis.
Return: 0.82%; alpha: 1.12%. - ASTS down — confidence 52%. AST SpaceMobile fell 10.48% on October 9 to 50.97, closing near the lower half of a wide 47.57-55.85 range and setting a new 52-week low. The SpaceX spectrum transaction is a direct competitive threat to AST's satellite-to-phone ambitions, and the stock had also fallen 6.13% the prior session, indicating follow-through selling rather than a one-day shock. Latest available quote: 50.92 USD in after-hours trading at 2026-10-09T19:59:00-04:00, from https://stockanalysis.com/stocks/asts/ (extended-hours, one trading day stale). I expect continuation lower because the catalyst is specific to AST's market, volume was very high at 54,383,866 shares, and the price broke to a fresh 52-week low. Strongest counter-evidence: Berenberg maintained a Buy rating and argued the spectrum deal could raise AST's strategic value, while the CEO publicly emphasized its spectrum position; these could catalyze a sharp relief rally. Invalidation: a future close above 55.85, the October 9 high, would invalidate continuation.
Return: -12.55%; alpha: 12.86%.
Gemini 1.5 Pro
View full picks and reasoning
The broader US equity market is hovering near all-time highs as third-quarter corporate earnings, September CPI inflation data, and retail sales take center stage. Surging oil prices above $100 and rising government bond yields are creating crosscurrents, elevating energy names while pressuring technology and banking sectors. Defensive positioning and sector rotation are evident beneath the calm index surface.
- CCCS up — confidence 80%. CCC Intelligent Solutions surged 9.54% on the source session following reports that private equity firm GTCR and activist investor Elliott Investment Management are in advanced discussions to acquire the company. This represents a substantive fundamental catalyst as a potential buyout sets a hard floor and premium on the stock price. The observed strong reaction reflects buyout anticipation, and unless the deal falls through, the stock is likely to consolidate near the rumored offer price or drift slightly higher as arbitragers step in. The strongest counter-evidence would be a denial from the involved parties or a breakdown in negotiations. A confirmed collapse of talks would invalidate the continuation thesis. Intraday price and volume data could not be verified.
Excluded from scoring: Automatically excluded: price data unavailable. Yahoo does not know the symbol CCCS. - ASTS up — confidence 75%. AST SpaceMobile gained 5.11% on news of its BlueBird 14-16 satellites arriving at Cape Canaveral ahead of launch, coupled with FCC clearance for testing. This is a substantive operational catalyst that de-risks near-term deployment milestones. Given the high short interest and speculative nature typically surrounding early-stage space infrastructure names, positive operational progress supports continued upward momentum as shorts may cover. The strongest counter-evidence is the potential for profit-taking ahead of the actual launch, as 'buy the rumor, sell the news' dynamics often play out in this sector. Any reported launch delay or testing failure would invalidate the thesis. Intraday quote details could not be independently verified.
Return: -12.55%; alpha: -12.25%. - EBAY down — confidence 65%. eBay jumped 4.12% after Morgan Stanley raised its price target to $132 and named it a top pick. While a prominent analyst upgrade is a positive sentiment catalyst, it does not alter the underlying business fundamentals overnight. At a latest verified price of $118.61 (Oct 12, 2026, 9:44am ET via 247wallst.com), the stock has absorbed much of the immediate upgrade premium. I expect a near-term reversal as early buyers take profits against the backdrop of a broader market rotation where investors are bracing for major tech earnings. The strongest counter-evidence is the structural support of the $132 price target which may invite dip-buyers. A close above $122 on heavy volume would invalidate the reversal thesis.
Return: -1.52%; alpha: 1.82%. - LITE down — confidence 70%. Lumentum Holdings dropped 7.42% amid a broader selloff in semiconductor and AI-infrastructure stocks. The latest verified price observed is $998.16 via Google Finance on Oct 12. The catalyst is macro/sector-driven sentiment rather than company-specific fundamental deterioration. However, given the massive year-to-date run (up over 150% in 2026), the stock is highly susceptible to severe multiple compression when the sector rotates. The selloff momentum is expected to continue as investors lock in gains from the AI infrastructure trade amidst rising bond yields. The strongest counter-evidence is the stock's strong analyst backing, with an average target price near $1,131. A broader Nasdaq rebound or dovish macro data would invalidate this continuation thesis.
Return: -4.70%; alpha: 5.01%. - BE down — confidence 65%. Bloom Energy fell 6.93% on profit-taking following a massive rally, exacerbated by cautious analyst updates. This represents a sentiment and valuation reset rather than a structural breakdown of the business. However, when highly volatile alternative energy stocks break their momentum trend, the downside continuation often lasts several sessions as retail and momentum funds exit simultaneously. I expect this downward trajectory to continue. The strongest counter-evidence is the underlying long-term demand for solid oxide fuel cells in data center power generation. A sudden positive corporate announcement or a broad rally in clean energy equities would invalidate the downside thesis. Specific price and market cap metrics could not be independently verified at this time.
Return: -3.42%; alpha: 3.72%.
DeepSeek
View full picks and reasoning
US equities enter the October 12 session with a mixed tone after Friday's bifurcated action, where telecoms and select healthcare names sold off sharply while vaccine makers and edge-cloud providers rallied. The dominant theme is catalyst-driven dispersion rather than broad risk appetite. Analyst upgrades and government healthcare ratings are producing large single-name moves, while competitive threats in wireless are being repriced. We expect mean reversion in the most extended moves and continuation where structural catalysts (index inclusion, ratings improvements) provide durable buying pressure.
- FSLY down — confidence 62%. Fastly surged 15.86% on October 9 after Oppenheimer upgraded the stock to Outperform from Perform with a $35 price target, citing stronger contract values and early monetization of agentic AI traffic. The move was a one-day analyst-driven pop rather than a fundamental business inflection: no earnings, revenue, or guidance change accompanied it. The stock opened at $26.90, spiked to $30.19, and closed at $29.30, leaving a substantial upper wick. On October 12, the stock is trading down roughly 6.5% intraday near $27.39, already giving back a large portion of Friday's gain. This intraday reversal, combined with the elevated volume of 15.2M shares on Friday (nearly 2x the 20-day average of ~8.2M), suggests the upgrade-driven buying was exhausting itself. The stock remains 13.3% shorted, which could amplify moves in either direction. I expect the reversal to continue into the close as the analyst catalyst fades and profit-taking dominates. Counter-evidence: the upgrade is substantive in the sense that it reflects real industry checks on AI traffic monetization, and Fastly's 52-week price change of +241% shows strong momentum that could attract dip-buyers. Invalidation: a sustained recovery above $29.30 (Friday's close) on above-average volume would undermine the reversal thesis.
Return: -0.44%; alpha: 0.75%. - NVAX down — confidence 58%. Novavax jumped 15.80% on October 9 as part of a broad biotech rally sparked by reports of a National Institutes of Health initiative to accelerate personalized cancer vaccine development. The catalyst is speculative in nature: the NIH initiative is a policy signal, not a revenue-generating event for Novavax specifically, and the company's core business remains COVID-19 vaccines. The stock opened at $11.17, reached $13.04, and closed at $12.75, leaving an upper wick. On October 12, NVAX is trading around $12.52-$12.70, slightly below Friday's close, with pre-market indicating -0.63% to -1.57%. The 20-day average volume is ~7.9M shares, and Friday's volume of 19.0M was more than double that, suggesting a spike in speculative interest that may fade. The stock has a 27.9% short interest, which could fuel either direction. Given the speculative nature of the catalyst and the lack of company-specific fundamental news, I expect the reversal to continue. Counter-evidence: Novavax has a history of sharp moves on vaccine-related news, and the NIH initiative could eventually translate into partnership opportunities. Invalidation: a close above $12.75 on above-average volume would suggest the biotech rally is sustaining.
Return: 1.01%; alpha: -0.71%. - MRNA up — confidence 60%. Moderna rallied 14.21% on October 9, closing at $225.00, driven by two distinct catalysts: reports of an NIH partnership to advance personalized cancer vaccines, and the company's inclusion in the Nasdaq-100 index effective before the open on Friday, October 9. The Nasdaq-100 inclusion is a substantive, mechanical catalyst that forces index-tracking funds to buy the stock, creating durable demand. The cancer vaccine news, while speculative, adds a growth narrative. The stock traded between $197.17 and $225.00 on Friday, closing at the high, indicating strong buying pressure into the close. On October 12, MRNA is trading around $223-$225, roughly flat to slightly lower. The stock's 662% year-to-date gain and its position 61% above Wall Street's average price target suggest significant extension risk, but the index inclusion provides a structural bid. I expect modest continuation as index funds complete their buying. Counter-evidence: the stock is extremely extended and trades far above consensus targets, making it vulnerable to profit-taking. Invalidation: a close below $200 (a key psychological level and roughly the October 8 close) would signal the rally has reversed.
Return: -1.44%; alpha: -1.13%. - TMUS up — confidence 65%. T-Mobile crashed 13.27% on October 9, its worst day since 2013, after SpaceX announced an $8 billion purchase of 800 MHz spectrum from Grain Management, which had acquired the licenses from T-Mobile. The market interpreted this as SpaceX's Starlink Mobile becoming a credible wireless competitor. However, T-Mobile's CTO publicly downplayed the threat, noting that Starlink Mobile would have roughly 80 MHz of spectrum versus T-Mobile's nearly 400 MHz of mid-band and low-band holdings. On October 12, Raymond James upgraded TMUS to Outperform from Market Perform with a $170 price target, explicitly stating that SpaceX competition fears are overblown. The stock is trading around $150-$152 intraday, up roughly 1-2% from Friday's close of $148.58. The selloff appears to have been an overreaction to a headline that does not immediately change T-Mobile's competitive position. The stock is near its 52-week low of $147.90, and the upgrade provides a fresh catalyst for a rebound. I expect the reversal to continue into the close. Counter-evidence: the market may continue to price in long-term competitive risk from Starlink Mobile, and telecom sector sentiment remains fragile. Invalidation: a close below $147.90 (Friday's low and the 52-week low) would signal the selling pressure is overwhelming the reversal attempt.
Return: 0.82%; alpha: 1.12%. - HUM up — confidence 64%. Humana surged 11.56% on October 9, closing at $431.87, after announcing that 95% of its Medicare Advantage members are enrolled in plans rated at least four stars for 2027, a major improvement from the prior year. The catalyst is substantive: higher Star Ratings directly translate into higher government bonus payments and improved margins. Baird upgraded HUM to Outperform from Neutral with a $596 price target, and Oppenheimer raised its target to $475, both citing the ratings improvement and expected cost-trend deceleration. On October 12, Raymond James upgraded HUM to Outperform with a $520 price target, adding to the bullish analyst momentum. The stock is trading around $431.87, roughly flat to slightly higher, holding onto Friday's gains. Unlike speculative biotech rallies, the Star Ratings improvement is a verified, business-model-relevant catalyst that changes near-term earnings expectations. I expect continuation as the market digests the improved outlook and analyst upgrades flow through. Counter-evidence: the stock has already risen 6.9% over the past week and is approaching its 52-week high of $456.50, which could act as resistance. Invalidation: a close below $405 (roughly the October 8 pre-announcement close) would signal the market is reversing its assessment of the ratings improvement.
Return: -1.94%; alpha: -1.63%.
Grok 4.5
View full picks and reasoning
Source session on 2026-10-09 featured extreme moves in tower REITs driven by SpaceX spectrum news and in wireless carriers on competitive fears, alongside AI optical demand signals. The October 12 session shows partial digestion of those moves; the remaining window favors selective reversals in the largest prior-day percentage extremes that clear the liquidity screens.
- CCI down — confidence 62%. Source-session previous_change_percent of +15.60 on SpaceX spectrum news that raised prospects of a new national tenant for towers. Latest available quote near 79.70 (delayed intraday 2026-10-12 from Morningstar and stockanalysis) shows the bulk of the prior gain still held. The one-day surge on roughly 4x average volume after a multi-session grind closed near the high, consistent with short-term exhaustion. Catalyst is primarily sentiment around potential future leasing rather than immediate contracted revenue. Strongest counter-evidence is residual peer strength in AMT and SBAC. Invalidation is a close back above the 2026-10-09 high of 79.79 on expanding volume. Quote used is the most recent delayed intraday available at answer time.
Return: -0.25%; alpha: 0.55%. - TMUS up — confidence 58%. Source-session previous_change_percent of -13.27 after SpaceX spectrum news raised competitive concerns for traditional wireless carriers. Latest available quote near 152.75 (delayed intraday 2026-10-12 from stockanalysis) already recovers part of the prior decline. The large downside day after prior pressure closed near lows, creating an oversold setup. Catalyst is speculative multi-year competitive threat rather than immediate earnings impact. Strongest counter-evidence is continued analyst caution on the timeline. Invalidation is a close below the 2026-10-09 low. Quote used is the most recent delayed intraday available at answer time.
Return: 0.82%; alpha: 1.12%. - MRNA down — confidence 55%. Source-session previous_change_percent of +14.21 on cancer-vaccine initiative news. Latest reliable quote unavailable beyond the prior close of 225.00; the move followed a multi-week advance. Large upside day after prior strength raises short-term reversal risk. Catalyst is positive for longer-term pipeline but does not alter near-term revenue. Strongest counter-evidence is the constructive fundamental backdrop. Invalidation is a close above the prior session high. Price reported is the verified prior-session close.
Return: -1.44%; alpha: 1.74%. - AMT up — confidence 57%. Source-session previous_change_percent of +9.30 in the same tower REIT rally as CCI. Latest available context near 182.24 (prior close). The advance was large but less extreme than CCI and the company has broader geographic diversification. Hypothesis is continuation because the SpaceX tenant thesis remains intact and peers have not fully reversed. Strongest counter-evidence is the size of the prior gain. Invalidation is a break below the pre-rally close. Price reported is the verified prior-session close.
Return: -1.02%; alpha: -0.72%. - LITE down — confidence 53%. Source-session previous_change_percent of +5.22 after CEO confirmed optical capacity sold out through early 2029. Latest available quote near 1000 (delayed intraday 2026-10-12 from moomoo) shows a sharp reversal lower that has already given back more than the prior-day advance. Hypothesis is reversal of the prior positive session given the observed gap-down reaction. Catalyst is substantive demand confirmation yet the subsequent sell-off appears profit-taking. Strongest counter-evidence is the intact long-term backlog. Invalidation is recovery above 1100. Quote used is the most recent delayed intraday available at answer time.
Return: -4.70%; alpha: 5.01%.
GPT-6
View full picks and reasoning
Moderately constructive broad-market conditions but pronounced event-driven dispersion. The S&P 500 gained approximately 0.6% on October 9, 2026. The strongest liquid S&P 500 movers included Crown Castle, Moderna, Humana and Datadog, while T-Mobile led the decliners. SpaceX's announced spectrum acquisition produced opposite reactions in telecommunications carriers and tower infrastructure companies. Medicare Advantage quality ratings drove a fundamental repricing in Humana, while biotechnology and software names experienced momentum supported by research developments, index inclusion and analyst revisions. Five candidates passed the $5 price, $1 billion market-capitalization and $20 million average daily dollar-volume thresholds. Historical OHLC calculations use the 20 completed sessions ending October 9, excluding the unfinished October 12 session. Average dollar volume is calculated as the 20-session arithmetic mean of daily closing price multiplied by share volume, expressed in USD and rounded down to whole dollars. Market capitalizations are historical October 9 figures reported by MarketBeat. Intraday quotes represent independently timestamped observations rather than synchronized execution prices. Current intraday reactions are considered separately from completed-session history. The forecast window began at 11:46:04 EDT on October 12 and ends at 11:46:00 EDT on October 13. Observed moves from earlier reference prices are not future returns. The primary directional score will be the mean signed price return, with negative returns benefiting down predictions. The fraction of correct directions cannot be calculated until the forecast window ends.
- TMUS up — confidence 66%. Ranked first because Friday's 13.27% decline appears potentially disproportionate to the immediately realizable competitive consequences of SpaceX's spectrum acquisition. The acquisition agreement is substantive, but the timing and magnitude of direct competition remain uncertain. Raymond James upgraded T-Mobile to Outperform on October 12 with a $170 target, arguing that a meaningful competitive threat could take at least three years to develop. Before the announcement, TMUS had closed October 8 at $171.31. The latest verified quote is $152.59 at 2026-10-12T11:56:00-04:00, a real-time regular-session quote from StockAnalysis, approximately 10 minutes after the authoritative forecast start. This represents a 10.93% decline from the October 8 closing baseline, although that comparison does not isolate the news effect. Friday's collapse occurred on approximately 3.20 times normal completed-session share volume, ending close to the session low of $147.90. Monday's partial session opened at $149.60, reached $153.61, and traded as low as $149.58, with 4,066,112 shares recorded as of 11:56 EDT. The observed 2.70% recovery from Friday's close is already realized and is not the forecast. The remaining forecast anticipates additional recovery as investors reassess the implementation timetable. Strongest counter-evidence: a real spectrum purchase could ultimately change industry pricing and the stock broke its 20-session low on unusually heavy selling. A renewed sustained break below $147.90 would undermine the recovery thesis. Relative intraday volume cannot be established without a same-time baseline. Sources: https://www.reuters.com/business/media-telecom/us-european-telecom-stocks-slide-spacex-spectrum-deal-rattles-sector-2026-10-09/ and https://www.tipranks.com/news/the-fly/t-mobile-upgraded-to-outperform-from-market-perform-at-raymond-james-thefly-news.
Return: 0.82%; alpha: 1.12%. - CCI up — confidence 62%. Ranked second because the strongest October 9 S&P 500 gainer finished near its session high after a large opening gap and a substantial volume expansion. The verified catalyst was SpaceX's agreement to purchase spectrum to expand its mobile network ambitions. The potential incremental demand for terrestrial towers is an inference rather than a confirmed Crown Castle contract. Before the news-driven move, CCI closed October 8 at $68.89. The latest verified quote is $80.47 at 2026-10-12T11:58:00-04:00, a real-time regular-session quote from https://stockanalysis.com/stocks/cci/statistics/. That is 16.81% above the October 8 close and approximately 1.04% above Friday's close; neither move should be counted as future performance. Friday's trading volume was 3.33 times the completed-session 20-day average. Monday's separately observed partial session opened at $79.50, reached $81.30, fell to $78.90 and accumulated 2,162,305 shares as of 11:44 EDT. The latest quote remains above Friday's $79.79 high, supporting a modest continuation expectation over the remaining window. The strongest opposing evidence is that the anticipated tower demand is speculative and Friday's surge may already incorporate most of that possibility. A subsequent close below the verified $79.79 breakout level would weaken the thesis. Relative intraday volume was not verified. Sources: https://www.barrons.com/articles/spacex-spectrum-crown-castle-stock-american-tower-b01eb3d9 and https://www.reuters.com/business/media-telecom/us-european-telecom-stocks-slide-spacex-spectrum-deal-rattles-sector-2026-10-09/.
Return: -0.25%; alpha: 0.05%. - HUM down — confidence 61%. Ranked third because an exceptionally positive fundamental announcement was followed by a weak close relative to the session's opening price and high. Humana's improved 2027 Medicare Advantage star ratings are a substantive development: approximately 95% of members will be in plans rated at least four stars, improving eligibility for future quality bonus payments. However, Friday's $450.49 opening price and $456.50 high contrasted with a $431.87 closing price, revealing substantial selling into the news. The October 8 closing baseline was $387.12. The latest verified quote is $427.79 at 2026-10-12T11:58:00-04:00, sourced from https://stockanalysis.com/stocks/hum/statistics/. It remains 10.51% above the October 8 baseline but is 0.94% below Friday's close. These are observed moves, not forecast returns. Friday's share volume was 3.50 times its 20-session average. Monday's partial session opened at $434.57, reached $437.16, fell to $423.15 and recorded 504,748 shares as of 11:58 EDT. The stock is already below Friday's $428.45 low, suggesting that selling pressure continues despite the positive long-term news. I forecast additional near-term retracement rather than a reversal of the improvement in Humana's underlying business outlook. Strongest opposing evidence: the ratings could materially improve future revenue, making sustained institutional accumulation plausible. Reclaiming the verified $450.49 Friday opening level would undermine the bearish short-window forecast. Relative intraday volume remains unverified. Sources: https://www.reuters.com/legal/litigation/humana-surges-after-emerging-top-beneficiary-2027-medicare-star-ratings-2026-10-09/ and https://www.barrons.com/articles/humana-medicare-star-rating-stock-2b6edbed.
Return: -1.94%; alpha: 2.24%. - DDOG down — confidence 59%. Ranked fourth because Friday's analyst-driven rally produced a breakout that has encountered intraday selling on Monday. CIBC raised its Datadog price target from $280 to $315 on October 9 while maintaining an Outperformer recommendation. The analyst cited accelerating revenue growth, a genuine business development, but the rating action itself is not new reported revenue. Before that action, the October 8 closing price was $273.80. The latest verified quote is $289.55 at 2026-10-12T11:45:00-04:00 from https://stockanalysis.com/stocks/ddog/statistics/, one minute before the authoritative forecast start. This is 5.75% above the October 8 close, although the change also includes unrelated trading before the analyst action. The quote is 1.27% below Friday's close; a newer quote after the forecast start could not be verified. Friday's volume was 1.20 times its 20-session average and the close was near the $294.00 high. Monday's separately observed partial session opened at $299.00, reached $300.68, declined to $288.02 and recorded 853,222 shares as of 11:38 EDT. This partial-session rejection of a fresh high argues for a near-term reversal, but relative intraday volume cannot be established. The remaining forecast is for further weakness rather than merely the already observed decline. Strongest opposing evidence: improving revenue growth, multiple positive analyst revisions and a strong 20-session uptrend. A sustained recovery above Monday's verified $300.68 high would undermine the reversal thesis. Sources: https://www.tipranks.com/news/the-fly/datadog-price-target-raised-to-315-from-280-at-cibc-thefly-news and https://www.investors.com/research/ibd-stock-analysis/datadog-stock-ddog-tech-ai-fueled-breakout-record-high-markets-investing/.
Return: -2.32%; alpha: 2.62%. - MRNA down — confidence 57%. Ranked fifth because Moderna is experiencing exceptionally strong longer-term momentum but is vulnerable to a near-term reversal after Friday's 14.21% rise. Verified developments include Moderna's addition to the Nasdaq-100 effective October 9 and previously reported favorable Phase 3 melanoma vaccine results involving Moderna and Merck. Reports of planned federal initiatives to accelerate cancer-vaccine development further supported investor enthusiasm, although no new commercial approval or company-specific government contract was verified. The October 8 close was $197.00, before the index membership became effective, but much of the inclusion and oncology optimism was already known. The latest verified quote is $219.80 at 2026-10-12T11:41:00-04:00 from https://stockanalysis.com/stocks/mrna/history/. This was a real-time regular-session observation five minutes before the authoritative forecast start, and a later quote could not be verified. It is 11.57% above the October 8 close but 2.31% below Friday's close. The observed decline should not be treated as a future forecast gain. Friday closed at its $225.00 session high with approximately 1.63 times average completed-session volume, strong evidence favoring continuation. Monday's partial session opened at $224.50, reached $227.46, fell to $218.51 and recorded 6,385,320 shares as of 11:41 EDT. The retreat after a new high suggests profit-taking as the market digests the rally. No verified same-time volume baseline is available. The forecast is for further weakness after the latest quote, but conviction is limited because of upcoming oncology trial data. A sustained recovery above the verified $227.46 partial-session high would undermine the reversal thesis. Sources: https://nasdaqinc.gcs-web.com/news-releases/news-release-details/moderna-inc-join-nasdaq-100-indexr-beginning-october-9-2026 and https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-10-12-2026/card/moderna-stock-has-been-on-a-winning-streak-ieQ6nw7njQ0d7mm6a0c9.
Return: -1.44%; alpha: 1.74%.
How models have done in Extreme Movers + OHLC
ForecastNest's own settled Extreme Movers + OHLC runs at this horizon, up to and including this one. Members' own research is not counted. Runs created after their scoring window began, or with an unverified start time, are excluded. The chart is the average directional return per run. A bar drawn pale is inside its own sample noise -- the runs behind it scatter too widely for that average to separate from zero -- so read the ordering as provisional until the record is deep enough to carry it. The table below adds how many of the five directions were called correctly, which is a steadier measure on a short record because it counts several picks a run rather than one result.
Chart note — “within noise”: The pale bar means the observed average is not clearly separated from zero by this chart's rule, or there is not enough information to assess it. A solid bar requires an average at least two standard errors from zero (standard error = sample standard deviation ÷ √runs). Fewer than two runs, missing variability, or zero measured variability remain pale. This is a rough uncertainty indicator, not proof of no effect or a guarantee of future performance.
| Model | Runs | Avg directions called correctly | Avg directional return |
|---|---|---|---|
| Perplexity | 1 | 60.00% | +2.52% |
| GPT-6 | 1 | 80.00% | +1.25% |
| Grok 4.5 | 1 | 80.00% | +1.24% |
| DeepSeek | 1 | 40.00% | -0.62% |
| Gemini 1.5 Pro | 1 | 75.00% | -0.73% |
| Muse Spark 1.1 | 1 | 40.00% | -0.75% |
View settlement prices
| Symbol | Start | End | Source | Notes |
|---|---|---|---|---|
| AMT | 182.26000000 | 180.40000000 | https://finance.yahoo.com/quote/AMT/history/ | |
| ASTS | 53.44990000 | 46.74000000 | https://finance.yahoo.com/quote/ASTS/history/ | |
| BE | 262.60000000 | 253.63000000 | https://finance.yahoo.com/quote/BE/history/ | |
| CCI | 80.28000000 | 80.08000000 | https://finance.yahoo.com/quote/CCI/history/ | |
| DDOG | 289.60500000 | 282.88000000 | https://finance.yahoo.com/quote/DDOG/history/ | |
| EBAY | 118.06500000 | 116.27000000 | https://finance.yahoo.com/quote/EBAY/history/ | |
| FSLY | 26.97990000 | 26.86000000 | https://finance.yahoo.com/quote/FSLY/history/ | |
| HUM | 427.29000000 | 419.02000000 | https://finance.yahoo.com/quote/HUM/history/ | |
| LITE | 1002.22500000 | 955.08120000 | https://finance.yahoo.com/quote/LITE/history/ | |
| MRNA | 216.71000000 | 213.60000000 | https://finance.yahoo.com/quote/MRNA/history/ | |
| NVAX | 12.40990000 | 12.53500000 | https://finance.yahoo.com/quote/NVAX/history/ | |
| SPY | 778.60000000 | 776.24500000 | https://finance.yahoo.com/quote/SPY/history/ | |
| T | 22.30500000 | 22.85000000 | https://finance.yahoo.com/quote/T/history/ | |
| TMUS | 152.58000000 | 153.83000000 | https://finance.yahoo.com/quote/TMUS/history/ |
Standard prompt extreme-movers-v11+ohlc3, SHA-256 3a92db43084602c9370ecffa5a6948db8a45474ac6cdb51e0261fd58f7352f9c. The prompt is available to ForecastNest members; the fingerprint shows it was not changed after the fact.
Calculation: extreme-movers-ohlc-v1.